Table 1.
Demographics, treatment, and clinical outcomes
| Asthma N = 13 | Nonasthma N = 25 | p value | |
|---|---|---|---|
| Age (years) | 14 (IQR: 10–16) | 14 (IQR: 12–16) | NS |
| Sex (women) | 4 (30.8%) | 18 (72.0%) | p = .02 |
| Race | N = 12 | N = 25 | NS |
| White | 2 (16.7%) | 2 (8.0%) | NS |
| Black | 7 (53.9%) | 7 (28.0%) | |
| Asian | 0 (0.0%) | 3 (12.0%) | |
| Other/multiracial | 3 (25.0%) | 13 (52.0%) | |
| Ethnicity | N = 11 | N = 25 | NSb |
| Hispanic/Latino | 1 (9.1%) | 9 (36.0%) | |
| Non‐Hispanic or Latino | 10 (90.9%) | 16 (64.0%) | |
| BMI % | 76.0 (IQR: 44.0–96.0, n = 11) | 76.5 (IQR: 35.0 to 90.0, n = 22) | NS |
| History of COVID exposure | 4 (30.8%) | 9 (36.0%) | NS |
| Days from onset of illness to presentation | 3.0 (IQR: 2.0–6.0) | 2.0 (IQR: 1.0 to 6.0) | NS |
| Oxygen requirement | 1 (7.7%) | 11 (44.0%) | p = .03 |
| Ventilatory support | 1 (7.7%) | 10 (40.0%) | NS |
| BIPAP | 3 (12.0%) | ||
| High flow oxygen | 1 (4.0%) | ||
| Mechanical ventilation | 1 (7.7%) | 6 (24.0%) | |
| None | 12 (92.3%) | 15 (60%) | |
| ECMO | 0 | 2 (8.0%) | |
| Days on ventilator | 4 | 9.5 (IQR: 6.0 to 14.0, n = 6) | |
| Medical management | |||
| Hydroxychloroquine | 5 (38.5%) | 14 (56.0%) | NS |
| Azithromycin | 4 (30.8%) | 7 (28.0%) | NS |
| Remdesivir | 0 | 8 (32.0%) | p = .03 |
| Anti‐IL1 | 0 | 4 (16.0%) | NS |
| Anti‐ IL6 | 2 (15.4%) | 3 (12.0%) | NS |
| Systemic steroids | 3 (23.1%) | 6 (24.0%) | NS |
| Discharge disposition | |||
| Discharged home | 13 (100%) | 23 (92.0%) | NS |
| Deceased | 1 (4.0%) | ||
| Remains admitted | 1 (4.0%) | ||
| Discharged on oxygen | 0 | 2 (8.0%) | |
| Length of stay (days) a | 4.0 (95% CI: 2.0–6.8) | 6.8 (95% CI: 3.6–10.8) | NS |
| ICU admission (Yes) | 4 (30.8%) | 13 (52%) | NS |
a
Median LOS and 95% confidence Interval (CI) is from Kaplan–Meier tables to adjust for censoring.
b Two asthmatics with no ethnicity reported were excluded from this analysis.